Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  International journal of pharmaceutics

• Publication date

  2004-09-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.IJPHARM.2004.05.034PMID 15363499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Clinical Laboratory Paradigm for Evaluating Medication Effects on Alcohol Consumption: Naltrexone and Nalmefene

  2003cited by this paper
• Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets.

  2002cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  2001cited by this paper
• Outcome variables in the evaluation of alcoholics' treatment: lessons from the Italian Assessment of Alcoholism Treatment (ASSALT) Project.

  1999influential reference
• A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.

  1999cited by this paper
• The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.

  1998cited by this paper
• The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group.

  1997cited by this paper
• Effect of naltrexone and its derivatives, nalmefene and naltrindole, on conditioned anticipatory behaviour and saccharin intake in rats

  1997cited by this paper
• A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

  1994cited by this paper
• Prevalence of DSM-IV Alcohol Abuse and Dependence

  1994cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1994cited by this paper
• Naltrexone and coping skills therapy for alcohol dependence. A controlled study.

  1992cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1992cited by this paper
• Opioidergic, serotonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage.

  1991cited by this paper
• Human pharmacology and abuse potential of nalmefene

  1991cited by this paper
• Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome.

  1991cited by this paper
• A double-blind placebo controlled study of male alcoholics given a subcutaneous disulfiram implantation.

  1987cited by this paper
• Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist

  1987cited by this paper
• Nalmefene: Intravenous safety and kinetics of a new opioid antagonist

  1986cited by this paper
• Disulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study

  1986cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat.

  1986cited by this paper
• Binding of a new opiate antagonist, nalmefene, to rat brain membranes.

  1985cited by this paper
• Alcohol interactions with brain opiate receptors.

  1983cited by this paper
• Disulfiram implantation: a trial using placebo implants and two types of controls.

  1980cited by this paper
• Disulfiram implantation. A placebo-controlled trial with two-year follow-up.

  1978cited by this paper
• An improved long‐acting delivery system for narcotic antagonists

  1978cited by this paper
• Disulfiram Implantation: Placebo, Psychological Deterrent, and Pharmacological Deterrent Effects

  1976cited by this paper
• Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction.

  1975cited by this paper
• Disulfiram implant: a controlled trial.

  1974cited by this paper

• Controlled delivery via hot-melt extrusion: A focus on non-biodegradable carriers for non-oral applications

  2023cites this paper
• Implantable Drug Delivery Systems

  2023cites this paper
• Development of Porous Polyurethane Implants Manufactured via Hot-Melt Extrusion

  2020cites this paper
• A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Long-Acting Injectable Formulation of Vanoxerine (Vanoxerine Consta 394.2 mg) for Cocaine Relapse Prevention

  2019cites this paper
• Efficacy and Tolerability of Long-Acting Injectable Formulation of Nalmefene (Nalmefene Consta 393.1 mg) for Opioid Relapse Prevention: A Multicentre, Open-Label, Randomised Controlled Trial

  2019cites this paper
• A REVIEW ON: RECENT MODERN IN IMPLANTABLE DRUG DELIVERY SYSTEM

  2018cites this paper
• Polydopamine Modified TiO2 Nanotube Arrays for Long-Term Controlled Elution of Bivalirudin and Improved Hemocompatibility.

  2017cites this paper
• Applications of ethylene vinyl acetate copolymers (EVA) in drug delivery systems.

  2017cites this paper
• Lipophilic nalmefene prodrugs to achieve a one-month sustained release.

  2016cites this paper
• POTENTIAL USE OF ETHYLENE VINYL ACETATE COPOLYMER EXCIPIENT IN ORAL CONTROLLED RELEASE APPLICATIONS: A LITERATURE REVIEW

  2015cites this paper
• In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene

  2015cites this paper
• Device-based controlled local delivery of anastrozol into peritoneal cavity: In vitro and in vivo evaluation

  2014cites this paper
• PAT tools for the control of co-extrusion implants manufacturing process.

  2013cites this paper
• Hydrophobic Polymers of Pharmaceutical Significance

  2012cites this paper
• Drugs for Long Acting Injections and Implants

  2012cites this paper
• Hierarchical Structure of Electrospun Composite Fibers for Long‐Term Controlled Drug Release Carriers

  2012cites this paper
• Implantable drug delivery systems: An overview

  2011cites this paper
• Evaluation of two polymeric blends (EVA/PLA and EVA/PEG) as coating film materials for paclitaxel-eluting stent application

  2011cites this paper
• In vivo biocompatibility of three potential intraperitoneal implants.

  2011cites this paper
• Opioid modulators for alcohol dependence

  2011cites this paper
• Analgesics, Centrally Acting

  2011cites this paper
• Preparation, characterization and properties of partially hydrolyzed ethylene vinyl acetate copolymer films for controlled drug release.

  2010cites this paper
• The Development of ProNeura Technology for the Treatment of Addictions

  2009influential citation
• Development of Opioid Transdermal Delivery Systems

  2009cites this paper
• Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence

  2009cites this paper
• Supercritical solvent impregnation of poly(ɛ-caprolactone)/poly(oxyethylene-b-oxypropylene-b-oxyethylene) and poly(ɛ-caprolactone)/poly(ethylene-vinyl acetate) blends for controlled release applications

  2008cites this paper
• Analgesics and Antipyretics

  2007cites this paper
• A type of esophageal stent coating composed of one 5-fluorouracil-containing EVA layer and one drug-free protective layer: in vitro release, permeation and mechanical properties.

  2007cites this paper
• Estimation of 5-fluorouracil-loaded ethylene-vinyl acetate stent coating based on percolation thresholds.

  2007cites this paper
• In‐vitro and in‐vivo characterization of a buprenorphine delivery system

  2006influential citation
• Optimization of the preparation of nalmefene-loaded sustained-release microspheres using central composite design.

  2006cites this paper
• Drug adjuncts for treating alcohol dependence.

  2006cites this paper
• Current advances in sustained-release systems for parenteral drug delivery

  2005cites this paper
• Development of medications for alcohol use disorders: recent advances and ongoing challenges

  2005cites this paper